List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1781773/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	13.7	1,625
2	Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, The, 2007, 370, 1687-1697.	13.7	918
3	Persistent Poststroke Hyperglycemia Is Independently Associated With Infarct Expansion and Worse Clinical Outcome. Stroke, 2003, 34, 2208-2214.	2.0	562
4	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	13.7	394
5	Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes, 2000, 49, 1319-1324.	0.6	330
6	Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia, 2005, 48, 2206-2212.	6.3	294
7	Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nature Genetics, 2001, 27, 218-221.	21.4	289
8	Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet, The, 2009, 373, 1780-1788.	13.7	270
9	Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet, The, 1993, 341, 1365-1369.	13.7	262
10	Insulin resistance is a risk factor for progression to Type 1 diabetes. Diabetologia, 2004, 47, 1661-1667.	6.3	203
11	Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 2016, 39, 1702-1710.	8.6	200
12	Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. Journal of Clinical Investigation, 2006, 116, 3258-3265.	8.2	197
13	Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia, 2009, 52, 1250-1257.	6.3	194
14	The Rising Incidence of Type 1 Diabetes Is Accounted for by Cases With Lower-Risk Human Leukocyte Antigen Genotypes. Diabetes Care, 2008, 31, 1546-1549.	8.6	191
15	Pancreatic Â-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes. Diabetes Care, 2004, 27, 2348-2355.	8.6	178
16	Disease Sensitivity and Specificity of 52 Assays for Glutamic Acid Decarboxylase Antibodies: The Second International GADAB Workshop. Diabetes, 1995, 44, 636-640.	0.6	139
17	Clinical and Magnetic Resonance Imaging Correlates of Hypothalamic–Pituitary–Adrenal Axis Function in Depression and Alzheimer's Disease. British Journal of Psychiatry, 1996, 168, 679-687.	2.8	139
18	The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. Journal of Clinical Neuroscience, 2002, 9, 618-626.	1.5	139

#	Article	IF	CITATIONS
19	Increase in Remission Rate in Newly Diagnosed Type I Diabetic Subjects Treated with Azathioprine. Diabetes, 1985, 34, 1306-1308.	0.6	135
20	Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes, 1999, 48, 2145-2149.	0.6	132
21	New-Onset Diabetes After Kidney Transplantation—Changes and Challenges. American Journal of Transplantation, 2012, 12, 820-828.	4.7	119
22	Insular Cortical Ischemia Is Independently Associated With Acute Stress Hyperglycemia. Stroke, 2004, 35, 1886-1891.	2.0	114
23	Markers on Distal Chromosome 2q Linked to Insulin-Dependent Diabetes Mellitus. Science, 1996, 272, 1811-1813.	12.6	109
24	Frequency and Temporal Profile of Poststroke Hyperglycemia Using Continuous Glucose Monitoring. Diabetes Care, 2006, 29, 1839-1844.	8.6	107
25	Double-Blind Controlled Trial of Azathioprine in Children With Newly Diagnosed Type I Diabetes. Diabetes, 1989, 38, 779-783.	0.6	106
26	Evidence That Nasal Insulin Induces Immune Tolerance to Insulin in Adults With Autoimmune Diabetes. Diabetes, 2011, 60, 1237-1245.	0.6	106
27	Binding of Cytoplasmic Islet Cell Antibodies Is Blocked by Human Pancreatic Glycolipid Extracts. Diabetes, 1988, 37, 645-652.	0.6	99
28	lodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. American Journal of Medicine, 1993, 95, 78-82.	1.5	96
29	Similar Peptides from Two β Cell Autoantigens, Proinsulin and Glutamic Acid Decarboxylase, Stimulate T Cells of Individuals at Risk for Insulin-Dependent Diabetes. Molecular Medicine, 1995, 1, 625-633.	4.4	96
30	High Level of Concordance Between Assays for Glutamic Acid Decarboxylase Antibodies: The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes, 1994, 43, 1005-1009.	0.6	90
31	Weight Gain in Early Life Predicts Risk of Islet Autoimmunity in Children With a First-Degree Relative With Type 1 Diabetes. Diabetes Care, 2009, 32, 94-99.	8.6	88
32	Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study. Pediatric Diabetes, 2019, 20, 574-583.	2.9	86
33	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020, 43, 3024-3033.	8.6	85
34	The Prognostic Value of Thyrotropin Receptor Antibody Measurement in the Early Stages of Treatment of Graves' Disease with Antithyroid Drugs. Thyroid, 1998, 8, 119-124.	4.5	83
35	Islet autoimmunity in infants with a Type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia, 2000, 43, 203-209.	6.3	82
36	The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Medicine, 2001, 2, 174-180.	2.2	79

#	Article	IF	CITATIONS
37	Effectiveness and side effects of thiazolidinediones for type 2Âdiabetes: realâ€life experience from a tertiary hospital. Medical Journal of Australia, 2004, 181, 536-539.	1.7	77
38	Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2016, 18, 772-783.	4.4	77
39	Severe hypoglycaemia and its association with psychological well-being in Australian adults with type 1 diabetes attending specialist tertiary clinics. Diabetes Research and Clinical Practice, 2014, 103, 430-436.	2.8	74
40	Analysis of Families at Risk for Insulin-Dependent Diabetes Mellitus Reveals that HLA Antigens Influence Progression to Clinical Disease. Molecular Medicine, 1995, 1, 576-582.	4.4	69
41	New classification and criteria for diagnosis of diabetes mellitus. Medical Journal of Australia, 1999, 170, 375-378.	1.7	68
42	The accelerator hypothesis and increasing incidence of type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 321-325.	2.3	65
43	The role of HbA1c in the diagnosis of diabetes mellitus in Australia. Medical Journal of Australia, 2012, 197, 220-221.	1.7	65
44	HLA genes associated with autoimmunity and progression to disease in type 1 diabetes. Tissue Antigens, 2003, 61, 146-153.	1.0	61
45	Islet-reactive T cells are a marker of preclinical insulin-dependent diabetes Journal of Clinical Investigation, 1992, 89, 1161-1165.	8.2	61
46	Environmental determinants of islet autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes. BMC Pediatrics, 2013, 13, 124.	1.7	59
47	Interferon-Î ³ Induces the Expression of HLA-A,B,C but Not HLA-DR on Human Pancreatic Î ² -Cells*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 1101-1109.	3.6	58
48	Creation of a multidisciplinary, evidence based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications. Diabetic Medicine, 2005, 22, 127-136.	2.3	56
49	Reactivity to Human Islets and Fetal Pig Proislets by Peripheral Blood Mononuclear Cells From Subjects With Preclinical and Clinical Insulin-Dependent Diabetes. Diabetes, 1991, 40, 1128-1133.	0.6	55
50	Desirable performance standards for HbAIc analysis a€ precision, accuracy and standardisation Consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clinical Chemistry and	2.3	55
51	Laboratory Medicine, 2007, 45, 1083-97. Type 1 diabetes: Lessons for other autoimmune diseases?. Journal of Autoimmunity, 2008, 31, 306-310.	6.5	55
52	Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes. JAMA Pediatrics, 2021, 175, 1227.	6.2	54
53	Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes. Obesity Research and Clinical Practice, 2014, 8, e178-e182.	1.8	52
54	Autoimmunity to Both Proinsulin and IGRP Is Required for Diabetes in Nonobese Diabetic 8.3 TCR Transgenic Mice. Journal of Immunology, 2008, 180, 4458-4464.	0.8	51

#	Article	IF	CITATIONS
55	Screening for New-Onset Diabetes After Kidney Transplantation. Transplantation, 2013, 96, 726-731.	1.0	48
56	Ganglioside Expression in Human Pancreatic Islets. Diabetes, 1989, 38, 1478-1483.	0.6	46
57	The Melbourne Preâ€Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing. Medical Journal of Australia, 1998, 169, 81-84.	1.7	45
58	Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. Diabetes Care, 2022, 45, 381-390.	8.6	43
59	Antibodies to Glutamic Acid Decarboxylase in At-risk and Clinical Insulin-dependent Diabetic Subjects: Relationship to Age, Sex and Islet Cell Antibody Status, and Temporal Profile. Journal of Autoimmunity, 1994, 7, 55-66.	6.5	42
60	Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial. Cardiovascular Diabetology, 2011, 10, 102.	6.8	42
61	Fournier's gangrene in a man on empagliflozin for treatment of TypeÂ2 diabetes. Diabetic Medicine, 2017, 34, 1646-1648.	2.3	42
62	Measurement of thyroid stimulating immunoglobulins in a new cell line transfected with a functional human TSH receptor (JPO9 cells), compared with an assay using FRTL-5 cells. Clinical Endocrinology, 1994, 40, 645-652.	2.4	41
63	High Frequency of Type 1B (Idiopathic) Diabetes in North Indian Children With Recent-Onset Diabetes. Diabetes Care, 2003, 26, 2697-2697.	8.6	40
64	Early Intervention for Diabetes in Medical and Surgical Inpatients Decreases Hyperglycemia and Hospital-Acquired Infections: A Cluster Randomized Trial. Diabetes Care, 2019, 42, 832-840.	8.6	40
65	Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrology Dialysis Transplantation, 2014, 29, 698-705.	0.7	37
66	Expression of Cytoplasmic Islet Cell Antigens by Rat Pancreas. Diabetes, 1987, 36, 982-985.	0.6	34
67	Comparison of Bolus and Infusion Protocols for Determining Acute Insulin Response to Intravenous Glucose in Normal Humans. Diabetes Care, 1993, 16, 911-915.	8.6	34
68	Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Molecular Medicine, 1995, 1, 625-33.	4.4	34
69	Universal Subsidized Continuous Clucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study. Diabetes Care, 2022, 45, 391-397.	8.6	34
70	lgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. Human Immunology, 1998, 59, 493-499.	2.4	33
71	Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary. Clinical Endocrinology, 2008, 68, 29-35.	2.4	33
72	64,000- <i>M</i> r Autoantigen in Type I Diabetes: Evidence Against Its Surface Location on Human Islets. Diabetes, 1987, 36, 1432-1440.	0.6	32

#	Article	IF	CITATIONS
73	Evaluation of a New, Rapid and Automated Immunochemiluminometric Assay for the Measurement of Serum Intact Parathyroid Hormone. Annals of Clinical Biochemistry, 1997, 34, 97-103.	1.6	32
74	The impact of socioâ€economic disadvantage on rates of hospital separations for diabetesâ€related foot disease in Victoria, Australia. Journal of Foot and Ankle Research, 2011, 4, 17.	1.9	32
75	A randomised controlled trial of high dose vitamin D in recent-onset type 2 diabetes. Diabetes Research and Clinical Practice, 2014, 106, 576-582.	2.8	32
76	Distinct Gut Virome Profile of Pregnant Women With Type 1 Diabetes in the ENDIA Study. Open Forum Infectious Diseases, 2019, 6, ofz025.	0.9	32
77	Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. Endocrine Reviews, 2021, 42, 584-604.	20.1	31
78	Ovarian sensitization to gonadotrophins by human growth hormone. Persistence of the effect beyond the treated cycle. Clinical Endocrinology, 1991, 35, 119-122.	2.4	30
79	Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease. Thyroid, 1995, 5, 171-176.	4.5	29
80	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. Contemporary Clinical Trials, 2020, 90, 105892.	1.8	29
81	Australasian Diabetes Data Network. Journal of Diabetes Science and Technology, 2016, 10, 1015-1026.	2.2	28
82	"lt Is Definitely a Game Changer― A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 410-416.	4.4	28
83	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. Diabetes Care, 2017, 40, 1494-1499.	8.6	28
84	Acute continuous hemofiltration with dialysis. Critical Care Medicine, 1992, 20, 1672-1676.	0.9	27
85	Glycohaemoglobin: a crucial measurement in modem diabetes management. Medical Journal of Australia, 1997, 167, 96-98.	1.7	27
86	Role of islet autoimmunity in the aetiology of different clinical subtypes of diabetes mellitus in young north Indians. Diabetic Medicine, 2000, 17, 275-280.	2.3	27
87	Assessment and management of inpatients with acute diabetes-related foot complications: room for improvement. Internal Medicine Journal, 2004, 34, 229-233.	0.8	27
88	Adults With Diabetes Distress Often Want to Talk With Their Health Professionals About It: Findings From an Audit of 4 Australian Specialist Diabetes Clinics. Canadian Journal of Diabetes, 2020, 44, 473-480.	0.8	26
89	Evaluation of an Algorithm to Guide Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion on How to Respond to Real-Time Continuous Glucose Levels: A randomized controlled trial. Diabetes Care, 2010, 33, 1242-1248.	8.6	25
90	Diabetes associated with immune checkpoint inhibition: presentation and management challenges. Diabetic Medicine, 2018, 35, 1283-1290.	2.3	25

#	Article	IF	CITATIONS
91	Assay for Islet Cell Antibodies With Rat Pancreas and Peroxidase Protein A. Diabetes Care, 1988, 11, 367-368.	8.6	24
92	Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clinical Trials, 2010, 7, S56-S64.	1.6	24
93	A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes. Diabetes Care, 2022, 45, 194-203.	8.6	24
94	Type 1 diabetes in pregnancy is associated with distinct changes in the composition and function of the gut microbiome. Microbiome, 2021, 9, 167.	11.1	23
95	Nesidioblastosis and Multifocal Pancreatic Islet Cell Hyperplasia in an Adult: Clinicopathologic Features and In Vitro Pancreatic. American Journal of Clinical Pathology, 1985, 84, 534-541.	0.7	22
96	Thyrotoxic, hypokalaemic periodic paralysis in Australasian men. Internal Medicine Journal, 2003, 33, 91-94.	0.8	22
97	Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2019, 21, 56-58.	4.4	22
98	An Algorithm Guiding Patient Responses to Real-Time-Continuous Glucose Monitoring Improves Quality of Life. Diabetes Technology and Therapeutics, 2011, 13, 105-109.	4.4	21
99	Expression of Class I MHC Proteins on RIN-m5F Cells Is Increased by Interferon-Â and Lymphokine-Conditioned Medium. Diabetes, 1986, 35, 1225-1228.	0.6	18
100	The Function of the Hypothalamic–Pituitary–Adrenal Axis in Alzheimer's Disease. British Journal of Psychiatry, 1994, 165, 650-657.	2.8	18
101	Pancreas size and exocrine function is decreased in young children with recentâ€onset Type 1 diabetes. Diabetic Medicine, 2020, 37, 1340-1343.	2.3	18
102	Reactivity to human islets and fetal pig proislets by peripheral blood mononuclear cells from subjects with preclinical and clinical insulin-dependent diabetes. Diabetes, 1991, 40, 1128-1133.	0.6	18
103	Antibodies to the Protein Tyrosine Phosphatases IAR and IA-2 are Associated with Progression to Insulin-Dependent Diabetes (IDDM) in First-Degree Relatives At-Risk for IDDM. Autoimmunity, 1998, 28, 15-23.	2.6	17
104	Higher body mass index in adults at diagnosis of the slowly progressive form of type 1 diabetes mellitus is associated with lower risk HLA genes. Diabetes Research and Clinical Practice, 2014, 104, e69-e71.	2.8	17
105	Low prevalence of latent autoimmune diabetes in adults in northern India. Diabetic Medicine, 2015, 32, 810-813.	2.3	17
106	Reproducibility of the First-Phase Insulin Response to Intravenous Glucose Is Not Improved by Retrograde Cannulation and Arterialization or the Use of a Lower Glucose Dose. Diabetes Care, 1995, 18, 1168-1173.	8.6	16
107	Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 2011, 94, 284-290.	2.8	16
108	Glucometric benchmarking in an Australian hospital enabled by networked glucose meter technology. Medical Journal of Australia, 2019, 211, 175-180.	1.7	16

#	Article	IF	CITATIONS
109	High prevalence of idiopathic (islet antibodyâ€negative) type 1 diabetes among Indian children and adolescents. Pediatric Diabetes, 2021, 22, 47-51.	2.9	16
110	New classification and criteria for diagnosis of diabetes mellitus. The Australasian Working Party on Diagnostic Criteria for Diabetes Mellitus. New Zealand Medical Journal, 1999, 112, 139-41.	0.5	16
111	Substance abuse in young patients with type 1 diabetes: easily neglected in complex medical management. Internal Medicine Journal, 2005, 35, 359-361.	0.8	15
112	Adult Human Pancreatic Islet Cells in Tissue Culture: Function and Immunoreactivity*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 681-685.	3.6	14
113	Do Glutamic Acid Decarboxylase Antibodies Improve the Prediction of IDDM in First-degree Relatives At Risk for IDDM?. Journal of Autoimmunity, 1994, 7, 873-879.	6.5	14
114	Islet-cell antibodies in malnutrition-related diabetes mellitus from North India. Diabetes Research and Clinical Practice, 1996, 34, 73-78.	2.8	14
115	A questionnaire for determining prevalence of diabetes related foot disease (Qâ€ĐFD): construction and validation. Journal of Foot and Ankle Research, 2009, 2, 34.	1.9	14
116	Redundancy in Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 669-678.	2.2	14
117	Structure of insulin/insulin-like growth factor-1 receptors on the insulinoma cell, RIN-m5F. Biochemical and Biophysical Research Communications, 1984, 124, 657-662.	2.1	13
118	Hyperinsulinemia Is Not a Cause of Cortisol-Induced Hypertension. American Journal of Hypertension, 1994, 7, 562-565.	2.0	13
119	Retrospective data for diabetic foot complications: only the tip of the iceberg?. Internal Medicine Journal, 2006, 36, 197-199.	0.8	13
120	Development of autoantibodies to islet antigens during childhood: implications for preclinical type 1 diabetes screening. Pediatric Diabetes, 2002, 3, 144-148.	2.9	12
121	Type 1 diabetes: a disease of developmental origins. Pediatric Diabetes, 2017, 18, 417-421.	2.9	12
122	Measurement of TSH receptor blocking immunoglobulins using3H-adenine incorporation into FRTL-5 and JPO9 cells: use in a child with neonatal hypothyroidism. Clinical Endocrinology, 1995, 42, 39-44.	2.4	11
123	Nephrogenic diabetes insipidus associated with foscarnet—a case report. Journal of Antimicrobial Chemotherapy, 1996, 37, 1179-1181.	3.0	11
124	Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 97, 57-62.	2.8	11
125	Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clinical Chemistry, 2017, 63, 1261-1270.	3.2	11
126	Long term risk of severe retinopathy in childhoodâ€onset type 1 diabetes: a data linkage study. Medical Journal of Australia, 2017, 206, 398-401.	1.7	11

#	Article	IF	CITATIONS
127	Comparison of Two Commonly Used Standard IVGTTs. Diabetes Care, 1992, 15, 1053-1055.	8.6	10
128	Aspirin usage in a large teaching hospital diabetes clinic setting. Diabetic Medicine, 1999, 16, 605-608.	2.3	10
129	Cerebrospinal fluid (CSF) rhinorrhoea occurring six days after commencement of bromocriptine for invasive macroprolactinoma. Australian and New Zealand Journal of Medicine, 2000, 30, 399-400.	0.5	10
130	The transition from knowing to doing: teaching junior doctors how to use insulin in the management of diabetes mellitus. Medical Education, 2003, 37, 689-694.	2.1	10
131	A simplified method to assess affinity of insulin autoantibodies. Clinical Immunology, 2010, 137, 415-421.	3.2	10
132	Higher frequency of vertebrateâ€infecting viruses in the gut of infants born to mothers with type 1 diabetes. Pediatric Diabetes, 2020, 21, 271-279.	2.9	10
133	An evaluation of community-based resources for management of diabetes-related foot disorders in an Australian population. Australian Health Review, 2009, 33, 671.	1.1	10
134	Insulin autoantibodies in patients with autoimmune diseases. Diabetes Research and Clinical Practice, 1992, 18, 107-112.	2.8	9
135	Clinical Prediction Tool To Identify Adults With Type 2 Diabetes at Risk for Persistent Adverse Glycemia in Hospital. Canadian Journal of Diabetes, 2021, 45, 114-121.e3.	0.8	9
136	First Randomized Controlled Trial of Hybrid Closed Loop Versus Multiple Daily Injections or Insulin Pump Using Self-Monitoring of Blood Glucose in Free-Living Adults with Type 1 Diabetes Undertaking Exercise. Journal of Diabetes Science and Technology, 2021, 15, 1399-1401.	2.2	9
137	Changes in pancreatic exocrine function in young atâ€risk children followed to islet autoimmunity and type 1 diabetes in the <scp>ENDIA</scp> study. Pediatric Diabetes, 2020, 21, 945-949.	2.9	9
138	Suboptimal glycemic control in adolescents and young adults with type 1 diabetes from 2011 to 2020 across Australia and New Zealand: Data from the Australasian Diabetes Data Network registry. Pediatric Diabetes, 2022, 23, 736-741.	2.9	9
139	Measurement of thyroid-stimulating immunoglobulins by incorporation of tritiated-adenine into intact FRTL-5 cells: a viable alternative to radioimmunoassay for the measurement of cAMP. Clinical Endocrinology, 1992, 37, 493-499.	2.4	8
140	Acute complications of dopamine agonist treatment for macroprolactinoma – how uncommon?. Journal of Clinical Neuroscience, 2004, 11, 825-828.	1.5	8
141	New haemoglobin A1c: the way it is reported is about to change?. Internal Medicine Journal, 2007, 37, 213-215.	0.8	8
142	Factors associated with insulinâ€induced weight gain in an Australian type 2 diabetes outpatient clinic. Internal Medicine Journal, 2016, 46, 834-839.	0.8	8
143	Glucose alert system improves health professional responses to adverse glycaemia and reduces the number of hyperglycaemic episodes in nonâ€critical care inpatients. Diabetic Medicine, 2018, 35, 816-823.	2.3	8
144	Insights into pituitary tumorigenesis: from Sanger sequencing to next-generation sequencing and beyond. Expert Review of Endocrinology and Metabolism, 2019, 14, 399-418.	2.4	8

#	Article	IF	CITATIONS
145	The methionine aminopeptidase 2 inhibitor ZGNâ€1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1215-1219.	4.4	8
146	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia, 2021, 64, 2432-2444.	6.3	8
147	Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial. Diabetes Technology and Therapeutics, 2022, 24, 666-671.	4.4	8
148	Lowerâ€limb amputation and diabetes: the key is prevention. Medical Journal of Australia, 2000, 173, 341-342.	1.7	7
149	Late-Onset Autoimmune Diabetes in Relatives of People with Type 1 Diabetes. Annals of the New York Academy of Sciences, 2003, 1005, 370-373.	3.8	7
150	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 2021, 23, 460-466.	4.4	7
151	Determinants of Cardiovascular Risk in 7000 Youth With Type 1 Diabetes in the Australasian Diabetes Data Network. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 133-142.	3.6	7
152	Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018, 8, e020274.	1.9	7
153	New classification and criteria for diagnosis of diabetes mellitus. Position Statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists. Medical Journal of Australia 1999 170 375-8	1.7	7
154	A prozone phenomenon interferes in islet cell antibody detection: Direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. Journal of Autoimmunity, 1988, 1, 109-117.	6.5	6
155	Clinical features and pathogenesis of thyrotoxicosis in adult Melanesians in Papua New Guinea. Clinical Endocrinology, 2000, 52, 261-266.	2.4	6
156	Hypothyroidism associated with therapy for multiâ€drugâ€resistant tuberculosis in Australia. Internal Medicine Journal, 2019, 49, 364-372.	0.8	6
157	Longitudinal prevalence of inpatient diabetes mellitus in an Australian hospital across five decades: 1972–2019. Internal Medicine Journal, 2021, 51, 814-815.	0.8	6
158	Women with type 1 diabetes exhibit a progressive increase in gut Saccharomyces cerevisiae in pregnancy associated with evidence of gut inflammation. Diabetes Research and Clinical Practice, 2022, 184, 109189.	2.8	6
159	Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Journal of Endocrinological Investigation, 1994, 17, 581-584.	3.3	5
160	New pieces in the puzzle of diabetes. Lancet, The, 1996, 348, S4.	13.7	5
161	Associations between diet, the gut microbiome and short chain fatty acids in youth with islet autoimmunity and type 1 diabetes. Pediatric Diabetes, 2021, 22, 425-433.	2.9	5
162	Glycaemic outcomes in Australasian children and adults with Type 1 Diabetes: failure to meet targets across the age spectrum. Internal Medicine Journal, 2021, , .	0.8	5

#	Article	IF	CITATIONS
163	INSULIN SECRETION AND IMMUNOâ€GENETIC MARKERS IN DIABETICS WITH SECONDARY FAILUREâ€~ OF ORAL HYPOGLYCEMIC AGENTS. Australian and New Zealand Journal of Medicine, 1985, 15, 209-212.	0.5	4
164	EVIDENCE AGAINST AN IMMUNOGENETIC BASIS FOR DIABETES IN CHRONIC PANCREATITIS. Australian and New Zealand Journal of Medicine, 1987, 17, 392-395.	0.5	4
165	Deficiencies in nutritional intake in patients admitted with diabetesâ€related foot complications. Nutrition and Dietetics, 2007, 64, 186-191.	1.8	4
166	Fulminant type 1 diabetes in Australia in the absence of humoral and cellular immune responses to pancreatic islet autoantigens. Diabetes Research and Clinical Practice, 2012, 95, e4-e6.	2.8	4
167	Immunotherapy in type I diabetes. Postgraduate Medicine, 1987, 81, 146-155.	2.0	3
168	Screening for preclinical type 1 diabetes in a discrete population with an apparent increased disease incidence. Pediatric Diabetes, 2000, 1, 193-198.	2.9	3
169	A Practical Limited Sampling Strategy to Predict Free Prednisolone Exposure and Glycemia in Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2014, 36, 18-23.	2.0	3
170	Recent advances in type 1 diabetes. Medical Journal of Australia, 2015, 203, 290-293.	1.7	3
171	Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia, 2020, 63, 885-886.	6.3	3
172	Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and recommendations. British Journal of Anaesthesia, 2021, 127, e5-e7.	3.4	3
173	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 2021, 179, 109000.	2.8	3
174	Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network. Diabetes, Obesity and Metabolism, 2022, 24, 354-361.	4.4	3
175	Diabetes Ward Management-Room for Improvement. Journal of Pharmacy Practice and Research, 2004, 34, 95-99.	0.8	2
176	Intense focal pituitary FDG uptake due to intravascular large B ell lymphoma in pyrexia of unknown origin. American Journal of Hematology, 2016, 91, 1167-1168.	4.1	2
177	Managing hyponatraemia secondary to primary polydipsia: beware too rapid correction of hyponatraemia. Internal Medicine Journal, 2017, 47, 956-959.	0.8	2
178	Evaluation of protocol amendments to the Environmental Determinants of Islet Autoimmunity (ENDIA) study during the COVIDâ€19 pandemic. Diabetic Medicine, 2021, 38, e14638.	2.3	2
179	Benchmarking care outcomes for young adults with type 1 diabetes in Australia after transition to adult care. Endocrinology, Diabetes and Metabolism, 2021, 4, e00295.	2.4	2
180	A Long-Term Evaluation of Facebook for Recruitment and Retention in the ENDIA Type 1 Diabetes Pregnancy-Birth Cohort Study. Journal of Diabetes Science and Technology, 2023, 17, 696-704.	2.2	2

#	Article	IF	CITATIONS
181	Problems with new criteria for diagnosis of diabetes mellitus. Medical Journal of Australia, 1999, 171, 108-109.	1.7	1
182	Cyclical Cushing's disease causing recurrent oedema and knee effusions. Internal Medicine Journal, 2005, 35, 201-202.	0.8	1
183	Glycaemic trajectory and predictors of suboptimal glycaemic control in people with type 2 diabetes. Internal Medicine Journal, 2020, 50, 1415-1418.	0.8	1
184	A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes. Metabolism Open, 2020, 5, 100021.	2.9	1
185	Factors that predict glycaemic response to sodiumâ€glucose linked transporter (SGLT) inhibitors. Internal Medicine Journal, 2021, 51, 515-519.	0.8	1
186	Assay for Cytoplasmic Islet Cell Antibodies Using Two-Color Immunofluorescence and Rat Pancreas. Advances in Experimental Medicine and Biology, 1988, 246, 63-69.	1.6	1
187	Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 2022, 24, 350-356.	4.4	1
188	Ovarian Sensitization to Gonadotrophins by Human Growth Hormone. Persistence of the Effect Beyond the Treated Cycle. Obstetrical and Gynecological Survey, 1992, 47, 60-61.	0.4	0
189	Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity. Journal of Endocrinological Investigation, 1994, 17, 547-552.	3.3	0
190	Prevention of xenograft rejection by masking donor HLA class I antigens. Journal of Endocrinological Investigation, 1994, 17, 553-557.	3.3	0
191	Overnight Counter-Regulatory Hormone Levels and Next Day Glycemia in Adults with Type 1 Diabetes During Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump with Low-Glucose Suspend. Diabetes Technology and Therapeutics, 2017, 19, 438-439.	4.4	0
192	Successful post-transition engagement can be predicted at the time of transition in type 1 diabetes. Diabetes Research and Clinical Practice, 2020, 163, 108023.	2.8	0
193	Natural History of Type 1 Diabetes. , 2011, , 279-292.		0
194	MON-457 One in Five Patients Develop Multiple Hormone Deficiencies Following Radiotherapy for Acromegaly or Cushing's Disease. Journal of the Endocrine Society, 2019, 3, .	0.2	0
195	Exercise habits and glucose management among older adults with type 1 diabetes using insulin pumps. Acta Diabetologica, 2022, , 1.	2.5	0
196	Screening for preclinical type 1 diabetes in a discrete population with an apparent increased disease incidence. Pediatric Diabetes, 2000, 1, 193-198.	2.9	0